What is the forecast for Zealand Pharma's share price?
Zealand Pharma A/S equity research forecasts compiled by biotechnology sector analysts project an average 12-month price target clustering around 506.67 Danish Krone, with institutional estimates ranging from a low of 303 Krone up to a high of 950.25 Krone. Valuation frameworks incorporate clinical development progress and commercialization milestones for its innovative peptide-based therapeutics targeting obesity, metabolic disorders, and rare diseases.
Related FAQs
A Pharma CEO is the Chief Executive Officer of a pharmaceutical corporation, serving as the top executive responsible for steering the overall strategic vision, global business operations, research and development pipelines, and financial performance...
Zealand Pharma A/S is a prominent Danish biotechnology enterprise focused on the discovery, design, and clinical development of innovative peptide-based medicines for treating metabolic diseases, obesity, diabetes, and rare gastrointestinal disorders...
The United States procures a substantial share of its pharmaceutical products and active ingredients from domestic manufacturing facilities, but it also heavily relies on international imports to fulfill overall healthcare and commercial demands.
Zealand Pharma A/S carries an average consensus 12-month analyst price target reflecting its prominent position in biotechnology and peptide-based therapeutics targeting metabolic diseases, obesity, and rare disorders.
Yes, Zealand Pharma A/S operates as a publicly traded biopharmaceutical enterprise, with its primary shares listed on the Nasdaq Copenhagen stock exchange and American Depositary Receipts trading over-the-counter.
Zealand Pharma attracts strong attention from biotechnology and healthcare growth investors due to its promising clinical pipeline in metabolic diseases, obesity treatments, and rare gastrointestinal disorders.
Zealand Pharma A/S, trading on the Copenhagen Stock Exchange and major international platforms, operates as a biotechnology enterprise focused on the discovery, design, and clinical development of peptide-based medicines for metabolic and gastrointes...
Institutional equity research analysts covering Zealand Pharma A/S (ZEAL) project a consensus 12-month average price target hovering around 506.67 Danish kroner per share. Individual broker forecasts range from a conservative low estimate of 303.
Quantitative equity models and biotech research analysts often suggest that Zealand Pharma holds significant upside potential relative to its long-term future cash flows, particularly if its flagship obesity and metabolic drug candidates successfully...